MARC record from Internet Archive

LEADER: 07368cam 2201093Ma 4500
001 ocm85820283
003 OCoLC
005 20200511194641.0
008 031007s2004 njua ob 001 0 eng d
006 m o d
007 cr un||a|a||||
040 $aDG1$beng$epn$cDG1$dOCLCQ$dDG1$dOCLCQ$dOCLCE$dIDEBK$dOCLCQ$dOCLCF$dOCLCO$dOCLCQ$dNLGGC$dYDXCP$dOCLCQ$dDEBBG$dDG1$dCHVBK$dLIP$dOCLCQ$dAU@$dOCLCO$dOCLCA$dU3W$dOCLCQ$dOCLCA
019 $a607393819$a607393825$a652250212$a666967093$a814463136$a824553588$a992820908$a1058050495$a1081122471
020 $a0471432024$q(Cloth)
020 $a9780471432029$q(Cloth)
020 $a047165616X$q(electronic bk.)
020 $a9780471656166$q(electronic bk.)
020 $a1280556730
020 $a9781280556739
024 7 $a10.1002/047165616X$2doi
035 $a(OCoLC)85820283$z(OCoLC)607393819$z(OCoLC)607393825$z(OCoLC)652250212$z(OCoLC)666967093$z(OCoLC)814463136$z(OCoLC)824553588$z(OCoLC)992820908$z(OCoLC)1058050495$z(OCoLC)1081122471
042 $adlr
050 4 $aRC271.C5$bM655 2004
060 4 $a2004 F-238
060 4 $aQZ 269$bM718 2004
072 7 $aMJ$2bicssc
082 04 $a616.99/4061$222
084 $a44.81$2bcl
084 $a44.47$2bcl
084 $aVS 9100$2rvk
084 $aXH 3200$2rvk
245 00 $aMolecular cancer therapeutics :$bstrategies for drug discovery and development /$cedited by George C. Prendergast.
260 $aHoboken, N.J. :$bWiley-Liss,$c℗♭2004.
300 $a1 online resource (xiv, 351 pages) :$billustrations
336 $atext$btxt$2rdacontent
337 $acomputer$bc$2rdamedia
338 $aonline resource$bcr$2rdacarrier
504 $aIncludes bibliographical references and index.
588 0 $aPrint version record.
506 $3Use copy$fRestrictions unspecified$2star$5MiAaHDL
520 $aMolecular Cancer Therapeutics covers state-of-the-art strategies to identify and develop cancer drug target molecules and lead inhibitors for clinical testing. It provides a thorough treatment of drug target discovery, validation, and development. The introductory chapters provide an overview of pathways to discovery and development of molecular cancer therapeutics. Subsequent chapters progress from initial stages of drug target discovery to drug discovery, development, and testing in preclinical and clinical models. Topics include drug lead screening, drug-to-lead development, proof-of-concept studies, medicinal chemistry issues, intellectual property concerns, and clinical development. This invaluable reference promotes understanding of steps involved in developing drug leads for industrial partnering and development. It provides an overview of the strategies for discovery and validation of drug target molecules, and discusses cell- and molecule-based drug screening strategies, as well as mouse models for cancer.; Coverage also includes how to refine drug leads for suitability in clinical testing, the special issues of clinical testing of molecular-targeted drugs, and intellectual property concerns.
533 $aElectronic reproduction.$b[Place of publication not identified] :$cHathiTrust Digital Library,$d2010.$5MiAaHDL
538 $aMaster and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002.$uhttp://purl.oclc.org/DLF/benchrepro0212$5MiAaHDL
583 1 $adigitized$c2010$hHathiTrust Digital Library$lcommitted to preserve$2pda$5MiAaHDL
505 0 $aMachine derived contents note: Preface. -- Chapter 1. Introduction. -- Chapter 2. Molecular Cancer Therapeutics: Will the Promise Be Fulfilled? -- Chapter 3. Cancer Genetics and Drug Target Selection. -- Chapter 4. RNA Interference in Mammals: Journey to the Center of Human Disease. -- Chapter 5. Applications and Issues for Tissue Arrays in Target and Drug Discovery. -- Chapter 6. Protein Transduction Strategies for Target and Mechanism Validation. -- Chapter 7. Drug Screening: Assay Development Issues. -- Chapter 8. Gene Microarray Technologies for Cancer Drug Discover y and Development. -- Chapter 9. Transgenic Mouse Models of Cancer. -- Chapter 10. Transgenic versus Xenograft Mouse Models of Cancer: Utility and Issues. -- Chapter 11. Pharmacodynamic Assays in Cancer Drug Discovery: From Preclinical Validation to Clinical Trial Monitoring. -- Chapter 12. Pharmacokinetic and Toxicology Issues in Cancer Drug Discovery and Development. -- Chapter 13. Clinical Development Issues. -- Chapter 14. Intellectual Property and Commercialization Issues in Drug Discovery.
650 0 $aCancer$xChemotherapy.
650 0 $aCancer$xImmunotherapy.
650 0 $aAntineoplastic agents$xDesign.
650 2 $aAntineoplastic Agents$xpharmacology.
650 2 $aNeoplasms$xdrug therapy.
650 2 $aDrug Delivery Systems.
650 2 $aDrug Evaluation.
650 2 $aNeoplasms$xgenetics.
650 2 $aPharmacogenetics.
650 7 $aAntineoplastic agents$xDesign.$2fast$0(OCoLC)fst00810598
650 7 $aCancer$xChemotherapy.$2fast$0(OCoLC)fst00845327
650 7 $aCancer$xImmunotherapy.$2fast$0(OCoLC)fst00845386
650 7 $aArzneimitteldesign$2gnd
650 7 $aChemotherapie$2gnd
650 7 $aCytostatikum$2gnd
650 7 $aImmuntherapie$2gnd
650 7 $aKrebs$gMedizin$2gnd
653 $aMolecular Cell Biology.
655 4 $aElectronic books.
700 1 $aPrendergast, George C.
776 08 $iPrint version:$tMolecular cancer therapeutics.$dHoboken, N.J. : Wiley-Liss, ℗♭2004$z0471432024$w(DLC) 2003022153
856 40 $3Google$uhttp://books.google.com/books?id=s5FrAAAAMAAJ
856 40 $3HathiTrust Digital Library, Limited view (search only)$uhttp://catalog.hathitrust.org/api/volumes/oclc/53186554.html
856 40 $3John Wiley$uhttps://doi.org/10.1002/047165616X
856 40 $3MyiLibrary$uhttp://www.myilibrary.com?id=55673
856 40 $3Wiley$uhttps://onlinelibrary.wiley.com/doi/book/10.1002/047165616X
856 40 $3Wiley$uhttp://onlinelibrary.wiley.com/book/10.1002/047165616X
856 40 $3Wiley$uhttp://0-onlinelibrary.wiley.com.pugwash.lib.warwick.ac.uk/doi/book/10.1002/047165616X
856 40 $3Wiley$uhttp://catalogimages.wiley.com/images/db/jimages/9780471432029.jpg
856 40 $aE-Books (Wiley)$uhttps://doi.org/10.1002/047165616X$zAuthentication may be required
856 41 $3MyiLibrary, Table of contents$uhttp://www.myilibrary.com?id=55673&ref=toc
856 41 $3Table of contents$uhttp://catdir.loc.gov/catdir/toc/wiley041/2003022153.html
856 42 $3Publisher description$uhttp://catdir.loc.gov/catdir/description/wiley041/2003022153.html
856 4 $uhttp://catdir.loc.gov/catdir/description/wiley041/2003022153.html$zFull text available from Wiley InterScience
938 $aProQuest MyiLibrary Digital eBook Collection$bIDEB$n55673
938 $aYBP Library Services$bYANK$n2943047
029 1 $aAU@$b000025031644
029 1 $aAU@$b000042835277
029 1 $aCHBIS$b010880829
029 1 $aCHNEW$b000928687
029 1 $aCHVBK$b480090092
029 1 $aCHVBK$b480904936
029 1 $aDEBBG$bBV043385592
029 1 $aDEBSZ$b484926543
029 1 $aGBVCP$b881916900
029 1 $aHEBIS$b276106377
029 1 $aNZ1$b12037914
994 $aZ0$bP4A
948 $hNO HOLDINGS IN P4A - 172 OTHER HOLDINGS